RxDoctor Payments Data

Joyce Stratmoen

Gerontology · Jonesboro, ARNPI 1841736170

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 93.4% of the total across 58 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 11 manufacturers reported payments, led by Travere Therapeutics, Inc. at 31.5% of the total. 2025 is the largest year on record at $641, 8.4 times the $77 reported in 2021.

$1,207in general payments, 2019–2025

Across 58 payments — averaging $20.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Travere Therapeutics, Inc.$380
  • Bayer$267
  • Novartis$236
  • Boehringer Ingelheim$106
  • Novo Nordisk$63
  • Vifor Pharma, Inc.$54
  • plus $100 from 5 others

What the payments were for

  • Food & beverage$1,12793%
  • Education$807%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,207 in reported general payments places this provider in the 70th percentile of 89 gerontology providers in Arkansas.

See all gerontology providers in Arkansas

Medicare billing

Part B allowed, 2024
$29,639
Medicare patients
330
Services billed
442

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
KerendiaFinerenone42$29,940
JardianceEmpagliflozin42$25,897
FarxigaDapagliflozin Propanediol13$13,238
VeltassaPatiromer Calcium Sorbitex14$11,821
Cinacalcet Hcl20$9,146
Calcitriol580$5,359
Hydralazine Hcl110$1,002
Allopurinol152$867
Potassium Chloride40$737
Bumetanide11$561
Terazosin Hcl60$552
Nifedipine ErNifedipine28$292
Losartan Potassium34$187
Cefdinir14$181
Furosemide28$163

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
BayerKerendia$267$29,94042 claims
Boehringer IngelheimJardiance$106$25,89742 claims
AstraZenecaFarxiga$35$13,23813 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 89 gerontology providers in Arkansas.

Other gerontology in Jonesboro

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →